|

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

RECRUITINGEarly 1Sponsored by Augusta University
Actively Recruiting
PhaseEarly 1
SponsorAugusta University
Started2020-10-14
Est. completion2027-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT04449198

Summary

The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Men and premenopausal women
* All races
* Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)

Exclusion Criteria:

* Clinical diagnosis of hepatic, cardiovascular, or renal disease
* Uncontrolled diabetes (HbA1C \>12%)
* Diabetic complications (i.e. neuropathy)
* Uncontrolled hypertension (\>140/90 mm Hg on therapy)
* Pregnancy
* Use of vasoactive medications

Conditions3

DiabetesHeart DiseaseType 1 Diabetes

Locations1 site

Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology
Augusta, Georgia, 30912
Ryan Harris, PhD, CEP706-721-5998ryharris@augusta.edu

Browse More Trials

Heart Disease trialsDiabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.